Back to top
more

Protagonist Therapeutics (PTGX)

(Delayed Data from NSDQ)

$53.90 USD

53.90
438,148

+0.07 (0.13%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $53.89 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

PetMed Rides on Solid Reorders & New Orders Amid Competition

by Zacks Equity Research

PetMed (PETS) strives to implement several strategies to revitalize the top line, focusing on advertising efficiency to boost new order sales and shifting sales to higher margin items.

    Zacks Equity Research

    Dicerna Pharmaceuticals (DRNA) in Focus: Stock Moves 6.2% Higher

    by Zacks Equity Research

    Dicerna Pharmaceuticals (DRNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

      Zacks Equity Research

      Pieris Pharmaceuticals (PIRS) Soars: Stock Adds 15.2% in Session

      by Zacks Equity Research

      Pieris Pharmaceuticals (PIRS) saw a big move last session, as its shares jumped more than 15% on the day, amid huge volumes.

        Zacks Equity Research

        PDL BioPharma, Inc. (PDLI) Jumps: Stock Rises 8.2%

        by Zacks Equity Research

        PDL BioPharma, Inc, (PDLI) was a big mover last session, as the company saw its shares more than 8% on the day amid huge volumes.

          Zacks Equity Research

          PDL BioPharma, Inc. (PDLI) Jumps: Stock Rises 8.2%

          by Zacks Equity Research

          PDL BioPharma, Inc. (PDLI) was a big mover last session, as the company saw its shares more than 8% on the day amid huge volumes.

            Zacks Equity Research

            The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals

            by Zacks Equity Research

            The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals

              Zacks Equity Research

              4 Top-Ranked Biotech Stocks Under $20 With Room for Growth

              by Zacks Equity Research

              We take a look at the biotech stocks with a potential for growth keeping in mind that the industry has witnessed a rebound in 2017 from last year's challenges.